ArticleThe Journal of pharmacology and experimental therapeutics2017
Effects of Acute and Chronic Treatments with Dopamine D
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.Physiology & behavior · 2019Pooled it
- Assessing behavioral reallocation after acute environmental manipulations using an asymmetric cocaine versus sucrose choice task in male and female rats.Psychopharmacology · 2026Article
- Xanomeline treatment attenuates cocaine self-administration in rats and nonhuman primates.Neuropharmacology · 2025Article
- Assessing behavioral reallocation after acute environmental manipulations using an asymmetric cocaine versus sucrose choice task in male and female rats.Research square · 2025Article
- Mechanistic and translational insights from preclinical cocaine choice procedures on the economic substitutability of cocaine and nondrug reinforcers.Neuroscience and biobehavioral reviews · 2025Review
- In vitro safety evaluation of dopamine D3R antagonist, R-VK4-116, as a potential medication for the treatment of opioid use disorder.PloS one · 2024Article
- 3,4-Methylenedioxypyrovalerone High-Responder Phenotype as a Tool to Evaluate Candidate Medications for Stimulant Use Disorder.The Journal of pharmacology and experimental therapeutics · 2023Article
- The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats.Journal of psychopharmacology (Oxford, England) · 2023Article
- Effects of acute and repeated administration of the selective MAddiction biology · 2022Article
- The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.British journal of pharmacology · 2022Review
- Ibudilast attenuates cocaine self-administration and prime- and cue-induced reinstatement of cocaine seeking in rats.Neuropharmacology · 2021Article
- Effects of Dopamine D1-Like Receptor Ligands on Food-Cocaine Choice in Socially Housed Male Cynomolgus Monkeys.The Journal of pharmacology and experimental therapeutics · 2021Article
- Medications Development for Treatment of Opioid Use Disorder.Cold Spring Harbor perspectives in medicine · 2021Review
- (±)VK4-40, a novel dopamine DBritish journal of pharmacology · 2020Article
- The Long-Acting D3 Partial Agonist MC-25-41 Attenuates Motivation for Cocaine in Sprague-Dawley Rats.Biomolecules · 2020Article
- Early Life Stress and the Onset of Obesity: Proof of MicroRNAs' Involvement Through Modulation of Serotonin and Dopamine Systems' Homeostasis.Frontiers in physiology · 2020Review
- The highly selective dopamine DNeuropharmacology · 2019Article
- The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as DJournal of medicinal chemistry · 2019Article
- Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors.Pharmacology, biochemistry, and behavior · 2018Article
- The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats.Neuropharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Morgane ThomsenAlcohol and Drug Abuse Research Center, McLean Hospital, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Laboratory of Neuropsychiatry, Psychiatric Centre Copenhagen, University of Copenhagen, Copenhagen, Denmark (M.T.); Drug Safety Research and Development, Pfizer, San Diego, California (P.B.); and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (S.S.N.) mthomsen@mclean.harvard.edu.
Andrew C BarrettAlcohol and Drug Abuse Research Center, McLean Hospital, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Laboratory of Neuropsychiatry, Psychiatric Centre Copenhagen, University of Copenhagen, Copenhagen, Denmark (M.T.); Drug Safety Research and Development, Pfizer, San Diego, California (P.B.); and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (S.S.N.).
Paul ButlerAlcohol and Drug Abuse Research Center, McLean Hospital, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Laboratory of Neuropsychiatry, Psychiatric Centre Copenhagen, University of Copenhagen, Copenhagen, Denmark (M.T.); Drug Safety Research and Development, Pfizer, San Diego, California (P.B.); and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (S.S.N.).
S Stevens NegusAlcohol and Drug Abuse Research Center, McLean Hospital, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Laboratory of Neuropsychiatry, Psychiatric Centre Copenhagen, University of Copenhagen, Copenhagen, Denmark (M.T.); Drug Safety Research and Development, Pfizer, San Diego, California (P.B.); and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (S.S.N.).
S Barak CaineAlcohol and Drug Abuse Research Center, McLean Hospital, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts (M.T., A.C.B., S.B.C.); Laboratory of Neuropsychiatry, Psychiatric Centre Copenhagen, University of Copenhagen, Copenhagen, Denmark (M.T.); Drug Safety Research and Development, Pfizer, San Diego, California (P.B.); and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (S.S.N.).
McLean Hospital · USUniversity of Copenhagen · DKHarvard University · US
Funding
Medications Development for Stimulant AbuseR01DA026946 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S · 2009 to 2019
$3.7MDRUG ABUSE RESEARCH TRAINING PROGRAMT32DA007252 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI MELLO, NANCY K. · 1991 to 2011
$3.0MSelective Muscarinic Receptor Ligands as Targets for Cocaine Addiction MedicationR00DA027825 · NIDA · MCLEAN HOSPITAL · PI THOMSEN, MORGANE HERMANN · 2012 to 2014
$710kCOCAINE SELF ADMINISTRATION IN DOPAMINE KNOCKOUT MICER29DA012142 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CAINE, SIMON BARAK · 1999 to 2003
$414kNIDA NIH HHS R00 DA027825NIDA NIH HHS R01 DA026946NIDA NIH HHS R29 DA012142NIDA NIH HHS T32 DA007252
Abstract
Dopamine D
Indexed as
FoodAminopyridinesAnimalsBenzamidesChoice BehaviorCocaineConditioning, OperantDopamine AgonistsDopamine AntagonistsDopamine D2 Receptor AntagonistsDose-Response Relationship, DrugDrug ToleranceIndolesLigandsMaleMorpholines3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indoleAminopyridinesBenzamidesCocaineDopamine AgonistsDopamine AntagonistsDopamine D2 Receptor AntagonistsDRD2 protein, ratDrd3 protein, ratIndolesLigandsMorpholinesN-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)but-2-enyl)-4-pyridine-2-ylbenzamidePF 592379PiperidinesPyridinesReceptors, Dopamine D2Receptors, Dopamine D3
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.